Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2025 07:55 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression

Lipid alterations in Alport syndrome are linked to impaired ABCA1 lipid efflux and the underlying renal injury processes of lipotoxicity and inflammation.